Abstract:
In New Zealand certain dosage forms are not readily available as a result of government policy on the funding of pharmaceuticals. Extemporaneous ophthalmic formulations are required for a variety of patients, and the challenge to demonstrate that such products are prepared in accordance with best practice. Extemporaneous compounding is considered an area of pharmaceutical activity that carries a high risk of error in terms of safety and quality. This can be increased by the number of aseptic manipulations.
